

November 11, 2025

<p>To, Sr. General Manager Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.</p> <p>Scrip Code: 544502</p>	<p>To, Sr. General Manager National Stock Exchange of India Limited Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai – 400 051.</p> <p>Trading Symbol: AMANTA</p>
---	--

Dear Sir/ Madam,

Sub: Outcome of Board Meeting

With reference to the captioned subject, we would like to inform that the Board of Directors of Amanta Healthcare Limited at its meeting held on 11th November, 2025 have inter-alia considered and approved:

1. The Standalone Un-Audited Financial Results of the Company for the quarter and half-year ended 30th Sept, 2025. (Copy is enclosed herewith)
2. Limited Review Report of the Auditors with unmodified opinion of the Company for the quarter and half-year ended 30th Sept, 2025. (Copy is enclosed herewith)

The detailed disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed herewith.

The Meeting Commenced at 04:00 PM. and concluded at 05:00 P.M.

You are requested to take the same on your records.

Thanking you.

Yours sincerely,

For AMANTA HEALTHCARE LIMITED

Dinodia Nikhita

Digitally signed by Dinodia Nikhita
DN: c=IN, o=Personal, title=BS66,
pseudoym=2110201e1d024716bc7c8b71ae2dc,
2.5.4.20=de5f8a3a2b09c32363a7f9e02233a7f0590355edec,
1c4d480b91a1a643a, postalCode=380028, st=Gujarat,
serialNumber=81b8b0656eb87ef922a9a611a0d1a8cb8f1009644
d8f8b068a02779a5f41685, cn=Dinodia Nikhita
Date: 2025.11.13 15:11:50 +05'30'

NIKHITA DINODIA
Company Secretary &
Compliance Officer
Membership No. 53362

Encl.: As above

Price Waterhouse Chartered Accountants LLP

Review Report

To
The Board of Directors
Amanta Healthcare Limited
8th Floor, Shaligram Corporates, C.J. Marg,
Ambli, Ahmedabad, 380058
Gujarat, India.

1. We have reviewed the unaudited financial results of Amanta Healthcare Limited (the "Company") for the quarter ended September 30, 2025 and the year to date results for the period April 01, 2025 to September 30, 2025, which are included in the accompanying 'Statement of Unaudited Financial Results for the quarter and six months ended September 30, 2025', the Statement of Assets and Liabilities as on that date and the Statement of Cash Flows for the half-year ended on that date (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. Attention is drawn to the fact that the financial results for the corresponding period for quarter ended September 30, 2024 and the year to date results for the period April 01, 2024 to September 30, 2024 and the statement of cash flows for the corresponding period from April 01, 2024 to September 30, 2024, as reported in the Statement have been approved by the Company's Board of Directors, but have not been subjected to review as the requirement of submission of quarterly financial results is applicable on listing of equity shares of the Company from the quarter ended June 30, 2025.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Price Waterhouse Chartered Accountants LLP, 17th Floor, Shapath V, Opp. Karnavati Club, S G Highway
Ahmedabad - 380 051, Gujarat, India
T: +91 (79) 69247156

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

Amanta Healthcare Limited


Review Report for the unaudited financial results for the quarter and six months ended September 30, 2025

Page 2 of 2

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse Chartered Accountants LLP

Firm Registration Number: 012754N/N500016



Devang Mehta
Partner
Membership Number: 118785
UDIN: 25118785BMLBK19377

Place: Ahmedabad


Date: November 11, 2025

AMANTA HEALTHCARE LIMITED							
Registered Office: 8Th Floor, Shaligram Corporates C.J. Marg, Ambli, Ahmedabad - 380058, Gujarat, India, CIN: L24139GJ1994PLC023944. Phone: +91 79 6777 7600, E-mail: info@amanta.co.in, Website: www.amanta.co.in							
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2025							
Sr.no.	Particulars	For the quarter ended			For the six months ended		(Rs. in lakhs)
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	For the year ended
		Un-audited	Un-audited	Un-audited (Refer note 2)	Un-audited	Un-audited (Refer note 2)	31.03.2025 Audited
I	Income						
	Revenue from operations	7,088.73	6,530.71	6,673.42	13,619.44	13,483.07	27,470.82
	Other income	7.07	96.09	20.73	103.16	35.30	138.52
	Total income	7,095.80	6,626.80	6,694.15	13,722.60	13,518.37	27,609.34
II	Expenses						
	Cost of material consumed	2,373.30	2,383.11	2,281.06	4,756.41	4,546.35	10,126.14
	Purchase of stock-in-trade	155.68	308.49	335.74	464.17	464.04	1,232.04
	Changes in inventories of finished goods, work-in-process and stock-in-trade	(192.33)	(879.20)	(226.55)	(1,071.53)	(212.49)	(1,952.65)
	Employee benefits expense	1,074.80	1,014.72	886.05	2,089.52	1,778.44	3,633.97
	Finance costs (Refer note 6)	515.16	628.69	632.25	1,143.85	1,576.91	2,794.79
	Depreciation and amortisation expense	466.30	464.09	459.97	930.39	919.95	1,839.89
	Other expenses	2,212.23	2,214.25	2,008.97	4,426.48	4,178.93	8,464.47
	Total expenses	6,605.14	6,134.15	6,377.49	12,739.29	13,252.13	26,138.65
III	Profit before exceptional item and tax for the period / year (I-II)	490.66	492.65	316.66	983.31	266.24	1,470.69
IV	Exceptional item (Refer note 5)	262.88	-	-	262.88	-	-
V	Profit before tax (III - IV)	227.78	492.65	316.66	720.43	266.24	1,470.69
VI	Tax expense						
	- Current Tax	190.12	165.19	65.62	355.31	65.62	362.49
	- Deferred Tax	(89.69)	(23.26)	25.34	(112.95)	11.12	61.40
	- Tax adjustment in respect of earlier year	6.60	-	-	6.60	-	(3.27)
	Total tax expenses	107.03	141.93	90.96	248.96	76.74	420.62
VII	Profit for the period/year (V - VI)	120.75	350.72	225.70	471.47	189.50	1,050.07
VIII	Other comprehensive income						
	Items that will not be reclassified to profit and loss						
	Remeasurement (loss) on the defined benefit plans	(13.40)	(13.41)	(13.07)	(26.81)	(26.24)	(53.62)
	Tax relating to remeasurement (loss) of the defined benefit plans	3.38	3.37	3.29	6.75	6.60	13.50
	Other comprehensive income (net of tax)	(10.02)	(10.04)	(9.78)	(20.06)	(19.64)	(40.12)
IX	Total comprehensive income (VII+VIII)	110.73	340.68	215.92	451.41	169.86	1,009.95
	Paid up equity share capital (Face value of Rs. 10/- each)	343.36	288.29	282.70	343.36	282.70	282.70
	Reserves excluding revaluation reserves as per balance sheet of previous accounting year						6,755.89
	Earnings per share (of Rs. 10/- each) (not annualised)						
	Basic and Diluted (Rs.)	0.35	1.22	0.80	1.37	0.67	3.71



Amanta Healthcare Limited		
Registered Office: 8Th Floor, Shaligram Corporates C.J. Marg, Ambli, Ahmedabad - 380058, Gujarat, India, CIN: L24139GJ1994PLC023944.		
Phone: +91 79 6777 7600, E-mail: info@amanta.co.in, Website: www.amanta.co.in		
Statement of Assets And Liabilities as at September 30, 2025		
	(Rs. in lakhs)	
Particulars	As at September 30, 2025	As at March 31, 2025
	Un-audited	Audited
Assets		
Non-Current Assets		
(a) Property, plant and equipment	20,178.45	20,767.53
(b) Capital work-in-progress	1,086.85	654.80
(c) Right-of-use assets	762.85	854.58
(d) Intangible assets	81.39	91.63
(e) Financial Assets		
(i) Loans	21.89	20.70
(ii) Investments	801.19	772.29
(iii) Other Financial Assets	87.98	91.57
(f) Non current tax assets (net)	0.11	0.11
(g) Other non-current assets	1,525.82	1,130.72
	24,546.53	24,383.93
Current Assets		
(a) Inventories	8,296.80	7,297.69
(b) Financial Assets		
(i) Trade receivables	4,718.41	5,008.47
(ii) Cash and cash equivalents	9,196.41	22.06
(iii) Bank balances other than cash and cash equivalents	1,044.03	325.67
(iv) Loans	57.45	45.22
(v) Other financial Assets	20.02	1.75
(c) Other current assets	951.90	1,091.06
	24,285.02	13,791.92
Total Assets	48,831.55	38,175.85
Equity And Liabilities		
Equity		
(a) Equity Share capital	3,882.94	2,882.94
(b) Other Equity	17,185.07	6,755.89
	21,068.01	9,638.83




Amanta Healthcare Limited		
Registered Office: 8Th Floor, Shaligram Corporates C.J. Marg, Ambli, Ahmedabad - 380058, Gujarat, India, CIN: L24139GJ1994PLC023944.		
Phone: +91 79 6777 7600, E-mail: info@amanta.co.in, Website: www.amanta.co.in		
Statement of Assets And Liabilities as at September 30, 2025		
	(Rs. in lakhs)	
Particulars	As at September 30, 2025	As at March 31, 2025
	Un-audited	Audited
Liabilities		
Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	12,312.32	13,235.75
(ii) Lease Liabilities	697.46	773.93
(b) Deferred tax liabilities (net)	2,802.43	3,019.08
	15,812.21	17,028.76
Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	5,438.14	6,263.86
(ii) Lease Liabilities	138.22	120.11
(iii) Trade payables		
(A) Total outstanding dues of micro enterprises and small	638.70	221.77
(B) Total outstanding dues of creditors other than micro	2,994.07	2,828.17
enterprises and small enterprises		
(iv) Other Financial Liabilities	441.72	349.99
(b) Contract liabilities	881.55	620.87
(c) Other current liabilities	275.89	190.88
(d) Provisions	897.37	800.96
(e) Current Tax Liabilities (net)	245.67	111.65
	11,951.33	11,508.26
Total Equity and Liabilities	48,831.55	38,175.85
For and on behalf of Board of Directors		
		
Bhavesh Patel		
Chairman and Managing Director		
DIN: 00085505		
Place: Ahmedabad		
Date: November 11, 2025		



Amanta Healthcare Limited		
Registered Office: 8Th Floor, Shaligram Corporates C.J. Marg, Ambli, Ahmedabad - 380058, Gujarat, India, CIN: L24139GJ1994PLC023944. Phone: +91 79 6777 7600, E-mail: info@amanta.co.in, Website: www.amanta.co.in		
Statement of Cash Flows for the six months ended September 30, 2025		
Particulars	(Rs. in lakhs)	
	Six months ended September 30, 2025	Six months ended September 30, 2024
	Un-audited	Un-audited (Refer note 2)
Cash Flow From Operating Activities		
Profit before tax	720.43	266.24
Adjustments for :		
Depreciation and amortization expense	930.39	919.95
Net unrealised loss / (gain) on foreign currency transactions	(1.30)	2.33
Exceptional item (Refer note 5)	262.88	-
Provision for doubtful debts on trade receivable	144.98	98.25
Finance costs	1,143.85	1,576.91
Interest Income	(30.15)	(0.58)
Liabilities written back to the extent no longer required	(18.18)	(36.66)
Unwinding of discount on security deposits	(0.41)	(0.21)
Changes in fair value of financial assets measured at fair value through profit and loss	(11.57)	(22.86)
Gain on sale of mutual fund	(15.50)	-
Operating profit before working capital changes	3,125.42	2,803.37
Movement in working capital:		
Adjustments for decrease / (increase) in operating assets:		
Inventories	(999.11)	(434.07)
Trade receivables	145.65	122.48
Loans	(13.42)	(14.38)
Other financial asset	(14.68)	17.89
Other assets	(227.81)	(411.89)
Adjustments for increase / (decrease) in operating liabilities:		
Trade payables	582.83	394.98
Other current financial liabilities	44.18	104.61
Contract liabilities	202.13	202.92
Other current liabilities	51.35	14.02
Short term provision	96.41	93.77
Cash generated from operations	2,992.95	2,893.70
Taxes paid (net of tax refund)	(228.02)	(98.47)
Net cash flow from operating activities	2,764.93	2,795.23
Cash flow from investing activities		
Payments for property, plant and equipment, intangible assets and capital work in progress	(970.97)	(854.61)
Investments in bank deposits (having maturity more than three months but less than twelve months)	(718.36)	(834.23)
Purchase of Mutual Fund	(420.00)	(350.00)
Sales of Mutual Fund	418.16	-
Interest received on deposits	30.15	0.58
Proceeds from disposal of property, plant and equipment	-	201.35
Net cash used in investing activities	(1,661.02)	(1,836.91)



Amanta Healthcare Limited		
Registered Office: 8Th Floor, Shaligram Corporates C.J. Marg, Ambli, Ahmedabad - 380058, Gujarat, India, CIN: L24139GJ1994PLC023944. Phone: +91 79 6777 7600, E-mail: info@amanta.co.in, Website: www.amanta.co.in		
Statement of Cash Flows for the six months ended September 30, 2025		
Particulars	(Rs. in lakhs)	
	Six months ended September 30, 2025	Six months ended September 30, 2024
	Un-audited	Un-audited (Refer note 2)
Cash flow from financing activities		
Repayment of non convertible debenture	-	(12,179.96)
Proceed from issue of equity shares	12,600.00	2,000.00
Share issue expenses	(1,665.16)	-
Proceeds from term loans -Secured	-	33.73
Repayment of term loans -Secured	(132.85)	(304.62)
Repayment of term loan -Unsecured	(51.18)	(36.78)
Proceeds from deposits from members	-	352.86
Repayment of deposits from members	(390.40)	(253.00)
Proceeds/payment from cash credit (net)	(858.71)	(606.61)
Proceeds from term loan from financial institutions	1,678.32	12,575.00
Repayment of term loans from financial institutions	(800.00)	(400.00)
Interest paid on non convertible debenture	-	(65.04)
Repayment of Non-Convertible Redeemable Preference Share	(1,124.20)	-
Dividend paid on Non-Convertible Redeemable Preference Share	(50.00)	(50.00)
Processing Fees on term loan from financial institutions	-	(381.00)
Interest paid on term loan	(104.34)	(123.78)
Interest paid for term loan from financial institutions	(689.48)	(699.70)
Interest paid on cash credit	(177.71)	(143.34)
Interest paid on deposits from members	(30.29)	(41.86)
Payment of other borrowings cost	(37.41)	(66.98)
Lease payments	(96.15)	(194.82)
Net cash flow from/(used) in financing activities	8,070.44	(585.90)
Net increase in cash and cash equivalents	9,174.35	372.41
Cash and cash equivalents as at beginning of the period	22.06	153.94
Cash and cash equivalents as at end of the period	9,196.41	526.35
Footnotes:		
Cash and cash equivalents as at end of the period:		
Balances with banks		
Balances in current accounts	9,190.02	503.77
Cash on hand	6.39	22.58
Cash and cash equivalents as per Balance Sheet	9,196.41	526.35
For and on behalf of Board of Directors  Bhavesh Patel Chairman and Managing Director DIN: 00085505 Place: Ahmedabad Date: November 11, 2025		



Notes:


- 1 The above financial results are prepared in compliance with Indian Accounting Standard ("Ind AS") as notified under section 133 of the Companies Act, 2013 ("the Act") [Companies (Indian Accounting Standards) Rules, 2015], as amended. The above financial results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 11, 2025.
- 2 The figures for the corresponding quarter and six months ended September 30, 2024 as reported in these unaudited financial results and the statement of cash flows for the corresponding period from April 01, 2024 to September 30, 2024 have been approved by the Company's Board of Directors but have not been subjected to review since the requirement of submission of quarterly financial results is applicable on listing of equity shares of the Company, which was from the quarter ended June 30, 2025. These figures are furnished by the management of the Company and were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on November 11, 2025.
- 3 The Company operates only in one business segment i.e. Manufacturing and sale of pharmaceutical products including contract manufacturing services provided to customer which constitutes single reportable segment in accordance with the requirements of Ind AS 108 "Operating Segments".
- 4 During the quarter ended September 30, 2025, the Company has completed its Initial Public Offer (IPO) where 10,000,000 equity shares of face value of Rs. 10 each have been issued at a price of Rs. 126 per share. The issue comprised of 100% fresh issue aggregating to Rs. 12,600 lakhs. Pursuant to IPO, the equity shares of the Company were listed on BSE Limited and National Stock Exchange of India Limited on September 09, 2025. The utilization of the IPO proceeds from fresh issue of Rs. 12,600 lakhs is summarized below: -

Particulars	Amount to be utilized as per prospectus (Rs. In lakhs)	Revised Cost of objects (Rs in lakhs)	Amount utilized upto September 30, 2025 (Rs. In lakhs)	Amount unutilized as at September 30, 2025 (Rs. In lakhs)
Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat	7,000.00	7,000.00	764.81	6,235.19
Funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up new manufacturing line for SVP at Hariyala, Kheda, Gujarat	3,013.11	3,013.11	-	3,013.11
General corporate purposes*	660.46	302.08	-	302.08
Issue Expenses*	1,926.43	2,284.81	2,265.21	19.60
Total	12,600.00	12,600.00	3,030.02	9,569.98

* The issue expenses are modified to the extent of GST payment made over the cost as per the Offer Document filed for the IPO as certified by Independent Chartered Accountant and affirmed by the monitoring agency. Consequent to this, general corporate purpose expenses are also modified and reduced to that extent.

- 5 The Company has incurred certain IPO related expenses. These expenses have been allocated on a rational basis. The cost of Rs. 1,719.16 lakhs (net of GST) allocated for issue of new shares has been adjusted against securities premium as permissible under Section 52 of the Companies Act, 2013 upon successful completion of Initial Public Offer (IPO). The cost of Rs. 262.88 lakhs (net of GST) allocated for listing of existing shares has been recognised in the Statement of Profit and Loss and disclosed as an exceptional item.
- 6 The finance costs for the six months period ended September 30, 2024 and year ended March 31, 2025 includes Rs. 309.73 lakhs, being cost of derecognition of financial liability consequent to the early redemption of non-convertible debentures.

For and on behalf of Board of Directors



Bhavesh Patel
Chairman and Managing Director
DIN: 00085505

Place: Ahmedabad
Date: November 11, 2025

